Michael Jin Casey1, Herwig-Ulf Meier-Kriesche. 1. Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida, Gainesville, Florida 32610–0224, USA.
Abstract
PURPOSE OF REVIEW: The utilization of calcineurin inhibitors (CNI) in kidney transplantation has dramatically improved short-term outcomes but significant gains in long-term outcomes have proved elusive. Nephrotoxicity is the major problem associated with CNIs and is responsible for the disappointing progress seen in long-term graft survival. In this review, we assess CNI efficacy as well as the latest strategies employed to limit long-term CNI nephrotoxicity. RECENT FINDINGS: Three CNI sparing strategies - CNI withdrawal, CNI avoidance, and CNI minimization - are evaluated with discussion of key studies such as the Efficacy Limiting Toxicity Elimination-Symphony and Spare-the-Nephron studies. Recent breakthroughs in transplant immunosuppression are discussed such as the BENEFIT and BENEFIT-EXT studies, which have led to the recent US Food and Drug Administratrion approval of belatacept, a novel T-cell costimulation blocker. SUMMARY: For now, CNIs remain the proven standard of care in modern immunosuppression. However, some novel agents may challenge the role CNIs play in kidney transplantation in the very near future.
PURPOSE OF REVIEW: The utilization of calcineurin inhibitors (CNI) in kidney transplantation has dramatically improved short-term outcomes but significant gains in long-term outcomes have proved elusive. Nephrotoxicity is the major problem associated with CNIs and is responsible for the disappointing progress seen in long-term graft survival. In this review, we assess CNI efficacy as well as the latest strategies employed to limit long-term CNI nephrotoxicity. RECENT FINDINGS: Three CNI sparing strategies - CNI withdrawal, CNI avoidance, and CNI minimization - are evaluated with discussion of key studies such as the Efficacy Limiting Toxicity Elimination-Symphony and Spare-the-Nephron studies. Recent breakthroughs in transplant immunosuppression are discussed such as the BENEFIT and BENEFIT-EXT studies, which have led to the recent US Food and Drug Administratrion approval of belatacept, a novel T-cell costimulation blocker. SUMMARY: For now, CNIs remain the proven standard of care in modern immunosuppression. However, some novel agents may challenge the role CNIs play in kidney transplantation in the very near future.
Authors: K A Newell; A Asare; I Sanz; C Wei; A Rosenberg; Z Gao; S Kanaparthi; S Asare; N Lim; M Stahly; M Howell; S Knechtle; A Kirk; W H Marks; T Kawai; T Spitzer; N Tolkoff-Rubin; M Sykes; D H Sachs; A B Cosimi; W J Burlingham; D Phippard; L A Turka Journal: Am J Transplant Date: 2015-10-13 Impact factor: 8.086
Authors: K A Newell; A K Mehta; C P Larsen; P G Stock; A B Farris; S G Mehta; D Ikle; B Armstrong; Y Morrison; N Bridges; M Robien; R B Mannon Journal: Am J Transplant Date: 2017-07-03 Impact factor: 8.086
Authors: Rebecca Crepeau; Abraham Matar; Thomas R Spitzer; Simon Robson; Vimukthi Pathiraja; David H Sachs; Christene A Huang; Raimon Duran-Struuck Journal: Comp Med Date: 2012-08 Impact factor: 0.982
Authors: A Paliege; J Bamoulid; F Bachmann; O Staeck; F Halleck; D Khadzhynov; S Brakemeier; M Dürr; K Budde Journal: Urologe A Date: 2015-10 Impact factor: 0.639
Authors: Christine Neudoerfl; Bernadett J Mueller; Cornelia Blume; Kerstin Daemen; Maja Stevanovic-Meyer; Jana Keil; Frank Lehner; Hermann Haller; Christine S Falk Journal: Front Immunol Date: 2013-02-28 Impact factor: 7.561